Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $103.9 million.

  • Corcept Therapeutics' Shares Outstanding (Weighted Average) rose 53.01% to $103.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.9 million, marking a year-over-year increase of 53.01%. This contributed to the annual value of $103.2 million for FY2024, which is 31.67% down from last year.
  • Per Corcept Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $103.9 million for Q3 2025, which was up 53.01% from $104.1 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $116.8 million for Q1 2021, and its period low was $102.8 million during Q1 2024.
  • In the last 5 years, Corcept Therapeutics' Shares Outstanding (Weighted Average) had a median value of $104.9 million in 2023 and averaged $107.2 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Shares Outstanding (Weighted Average) surged by 195.77% in 2021, and later crashed by 925.03% in 2022.
  • Corcept Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $115.7 million in 2021, then dropped by 7.67% to $106.8 million in 2022, then decreased by 3.02% to $103.6 million in 2023, then dropped by 0.32% to $103.2 million in 2024, then increased by 0.67% to $103.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $103.9 million for Q3 2025, versus $104.1 million for Q2 2025 and $104.1 million for Q1 2025.